PRESS RELEASE published on 09/03/2024 at 14:30, 1 year 8 months ago Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1 MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF published on 09/02/2024 at 13:05, 1 year 8 months ago Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1 COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1
BRIEF published on 09/02/2024 at 13:05, 1 year 8 months ago La FDA de Taïwan approuve le vaccin COVID-19 de Moderna ciblant la variante JN.1 du SRAS-CoV-2 Moderne Vaccin Contre Le Covid-19 Spikevax SARS-CoV-2 JN.1 FDA De Taïwan
PRESS RELEASE published on 09/02/2024 at 13:00, 1 year 8 months ago Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 Moderna receives approval for updated COVID-19 vaccine formulation targeting SARS-CoV-2 variant JN.1 from Taiwan FDA. Regulatory decisions globally expected soon COVID-19 Vaccine Moderna Spikevax SARS-CoV-2 Variant Taiwan FDA
BRIEF published on 08/29/2024 at 14:05, 1 year 8 months ago Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination COVID-19 Moderna Vaccination Health Campaign Public Awareness
BRIEF published on 08/29/2024 at 14:05, 1 year 8 months ago Moderna lance une campagne nationale de sensibilisation pour favoriser la vaccination contre la COVID-19 Moderne COVID 19 Vaccination Campagne De Santé Sensibilisation Du Public
PRESS RELEASE published on 08/29/2024 at 14:00, 1 year 8 months ago Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination Moderna launches 'Do It For You & Them' campaign to drive vaccination rates in the U.S. and inform about COVID-19 risks & impact, updated vaccines available for KP.2 variant COVID-19 Moderna Awareness Campaign KP.2 Variant Vaccination Rates
BRIEF published on 08/23/2024 at 13:05, 1 year 8 months ago Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) Public Health European Commission MRNA Technology RSV Vaccine Moderna Approval
BRIEF published on 08/23/2024 at 13:05, 1 year 8 months ago Moderna reçoit l'approbation de la Commission européenne pour son vaccin contre le VRS mRESVIA(R) Santé Publique Vaccin Contre Le VRS Commission Européenne Technologie De L'ARNm Approbation De Moderna
PRESS RELEASE published on 08/23/2024 at 13:00, 1 year 8 months ago Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) Moderna receives European Commission approval for mRESVIA(R) (mRNA-1345) vaccine to fight RSV in adults aged 60+; significant breakthrough beyond COVID-19 European Commission Moderna Vaccine RSV MRESVIA
Published on 05/13/2026 at 00:00, 1 hour ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 1 hour 25 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 3 hours 5 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 3 hours 18 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 10 hours 30 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 23:47, 1 hour 12 minutes ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 2 hours 34 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 4 hours 38 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 5 hours 25 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 5 hours 25 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:15, 6 hours 45 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 6 hours 45 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 6 hours 50 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 6 hours 50 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 7 hours 10 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
